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Abstract
Background: Mice with genetic deficiencies in adaptive immunity are used for the grafting of human cells or 
pathogens, to study human diseases, however, the innate immune responses to xenografts in these mice has received 
little attention. Using the NOD/SCID Plasmodium falciparum mouse model an analysis of innate defences responsible 
for the substantial control of P. falciparum which remains in such mice, was performed.
Methods: NOD/SCID mice undergoing an immunomodulatory protocol that includes, clodronate-loaded liposomes 
to deplete macrophages and an anti-polymorphonuclear leukocytes antibody, were grafted with human red blood 
cells and P. falciparum. The systematic and kinetic analysis of the remaining innate immune responses included the 
number and phenotype of peripheral blood leukocytes as well as inflammatory cytokines/chemokines released in 
periphery. The innate responses towards the murine parasite Plasmodium yoelii were used as a control.
Results: Results show that 1) P. falciparum induces a strong inflammation characterized by an increase in circulating 
leukocytes and the release of inflammatory cytokines; 2) in contrast, the rodent parasite P. yoelii, induces a far more 
moderate inflammation; 3) human red blood cells and the anti-inflammatory agents employed induce low-grade 
inflammation; and 4) macrophages seem to bear the most critical function in controlling P. falciparum survival in those 
mice, whereas polymorphonuclear and NK cells have only a minor role.
Conclusions: Despite the use of an immunomodulatory treatment, immunodeficient NOD/SCID mice are still able to 
mount substantial innate responses that seem to be correlated with parasite clearance. Those results bring new 
insights on the ability of innate immunity from immunodeficient mice to control xenografts of cells of human origin 
and human pathogens.
Background
Defences against foreign cells, including pathogens, rely
on both innate or non-adaptive responses, and adaptive
or antigen-specific immune responses. However, modern
immunology has focused primarily or almost exclusively
on the latter.
Therefore, various strains of mice having a genetic defi-
ciency in cells responsible for adaptive immunity (i.e. T
and B lymphocytes) have been selected, which have been
used for the grafting of xenogenic cells, particularly those
of a human origin. Indeed, the vast majority of these
studies have focused on the grafting of human lympho-
cytes, haematopoietic stem cells and to a lesser extent
tumor cells [1]. However, it was previously shown that
one can take advantage of these immunocompromized
mice to develop a mouse model for human malaria.
The initial report that bovine red blood cells (RBC)
injected intra-peritoneally in SCID mice could cross the
peritoneum and colonize the peripheral blood [2] was an
incentive to repeat the experiment using human red
blood cells (HuRBC). Although there was regrettably no
understanding of the underlying mechanism of transport
through the peritoneum, SCID mice harbouring up to 70
- 80% HuRBC among total RBC in mice peripheral blood
were obtained [3].
However, when Plasmodium falciparum was injected
into SCID mice, the parasites became pycnotic within
hours in erythrocytes. After excluding a potential toxicity
of mouse serum by in vitro methods, [3], it was hypothe-
sized that innate immune defences could constitute the
main limiting factor in parasite survival, and this was
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confirmed by employing agents able to control mac-
rophages (MP) and other cells involved in innate defences
[4,5]. Further steps were performed in an empirical man-
ner. The model was improved by moving from the origi-
nal SCID mouse to the NIHIII (Beige Xid Nude) mouse,
then to the NOD/SCID mouse that have more defective
innate immunity, and by identifying two components
which, when combined, allowed to obtain a stable P. falci-
parum parasitaemia in some of the NOD/SCID mice [6]
(namely: liposomes encapsulating dichloromethylene-
diphosphonate, named clo-lip [5] and a monoclonal anti-
body (NIMP-14) [4] directed to mouse polymorphonu-
clear cells (PMN)).
Though this empirical approach demonstrated the fea-
sibility of the objective, and could be applied to vaccine
development [6,7] and drug screening [8], the control of
innate defences was far from optimal in this P. falciparum
blood stage rodent model. Indeed, the P. falciparum para-
sitaemia remained stable for extended periods of time, up
to four months only in a minor subset of mice, whereas it
was cleared within a few days in the majority of the ani-
mals.
The above data stress the importance of innate
defences and are in agreement with long standing obser-
vations made in humans. However, despite their crucial
importance innate defences have been far less studied
than adaptive responses, and remain poorly known.
Innate responses in P. falciparum infected patients were
recently analysed in detail and this unveiled several dra-
matic modifications in the phenotypes and functions of
blood monocyte/macrophage populations [9].
To complement the above descriptive analysis in
humans by an experimental approach in a model, it was
decided to perform in the P. falciparum NOD/SCID
model a systematic and stepwise analysis of innate cell
responses and inflammation mediators produced in
response to the grafting of HuRBC, of P. falciparum, as
well as to agents employed to control innate defences.
Results bring new insights about the role and potency of
innate defences against human xenografts, such as
HuRBC, and human pathogens, such as P. falciparum.
Methods
Mice
Two to six months old male and female NOD/SCID mice
were used. They were purchased from Charles River, and
kept in an A3 animal house, i.e. in sterile isolators. They
were housed in sterilized cages equipped with filter tops
during the experimentation. Mice were provided with
autoclaved tap water and a γ-irradiated pelleted diet ad
libitum. They were manipulated under pathogen free
conditions using laminar flux hoods. All animals were
treated according to the French legislation.
Human red blood cells
Human whole blood was provided by the French blood
bank (Etablissement français du sang, Paris, France).
Blood donors had no history of malaria and all the blood
groups were used without observing any difference on
parasite survival. Whole blood was washed three times by
centrifugation at 900 ×g, 5 minutes at room temperature
and buffy coat was separated in order to eliminate white
blood cells and platelets. Packed HuRBC were suspended
in SAGM (Adenine, Glucose and mannitol solution) and
kept at 4°C for a maximum of 2 weeks. Before use HuRBC
were washed three times in RPMI-1640 medium (Gibco/
BRL, Grand Island, N.Y.) supplemented with 1 mg hypox-
anthine per liter (Sigma, St Louis, MO) and warmed 10
minutes at 37°C.
Parasite cultures
The P. falciparum 3D7 clone was employed in this study.
This parasite strain was maintained in vitro at 5% haema-
tocrit in complete culture medium at 37°C in a candle jar.
This medium contained RPMI-1640 medium (Gibco/
BRL), 35 mM HEPES (Sigma), 24 mM NaHCO3, 0.5%
albumax (Gibco/BRL) and 1 mg of hypoxanthine (Sigma)
per liter. Cryopreserved parasites were thawed using the
glycerol/sorbitol method [10] and used for the further
experiments.
A non-lethal rodent parasite strain Plasmodium yoelii
XNL1.1 was preserved in 500 μl aliquot of cryo-preserv-
ing buffer at -80°C at 22% parasitaemia. The strain was
thawed at room temperature, diluted twice in RPMI-1640
medium followed by the injection of 50 × 106 parasite
directly into the mice.
Immunomodulatory agents and suppression of innate 
immunity
Numerous attempts were made to increase the success
rate of the grafting of infected RBC. Clo-lip (provided by
N. Van Rooijen) was injected through intraperitoneal
(i.p.) route in order to reduce the number of tissue MP, as
described previously [5]. The anti-PMN monoclonal anti-
body NIMP-R14 [4] was purified from a hybridoma
kindly provided by Dr. M. Strath (National Institute for
Medical Research, London, UK). Its activity was com-
pared to that of two other anti-PMN monoclonal anti-
bodies: RB6-8C5 (purified from the hybridoma kindly
provided by Geneviève Milon (Institut Pasteur, Paris,
France) and 1A8 (purchased from BioXcell, Lebanon).
The NIMP-R14 monoclonal antibody was used in all the
studies, unless specified. Various agents (all purchased at
Sigma, unless specified) were used to further reduce
innate immunity such as dexamethasone (1-5 mg/Kg/
day), TGF-β100 ng - 1 μg/day) (PeproTech, Rocky Hill,
NJ), cyclophosphamide (75 mg/kg/day), cisplatinium (1-
10 mg/Kg/day), and TMβ-1 monoclonal antibody thatArnold et al. Malaria Journal 2010, 9:197
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targets NK cells (1 mg/kg/day). The effect of splenectomy
and of irradiation (100 - 300 cGy) was also tested. Other
experiments evaluated the addition of metabolic agents
such as pABA (400 mg/kg/day), and folinic acid (400 mg/
kg/day), or of antioxidants, such as vitamin E (20 mg/Kg/
day; Nepalm, Cenexi, Fontenay sous bois), N-acetyl
cysteine (100 mg/kg/day), trolox (4 - 100 mg/kg/day), 8-
aminoguanidine (100 mg/Kg/day).
Chemical immunomodulation protocol and mouse 
infection
In the current study, a previously described immuno-
modulation protocol was employed [11], modified as
described in [12]. On day -13, each mouse received a dose
of 10 mg/kg of mAb NIMP-R14 by i.p. injection. On day -
12, each mouse received 0.2 ml of the suspension of clo-
lip by the same route. On days -9, -6, -3 each mouse
received 0.5 ml of HuRBC i.p. mixed with a dose of 10
mg/kg of mAb NIMP-R14 and 0.2 ml of clo-lip. On day 0
mice were infected with 500 μl HuRBC parasitized by P.
falciparum at a parasitaemia of 1% (all the developmental
forms, i.e. trophozoite, schizont and rings, were present)
mixed with a dose of 10 mg/kg of NIMP-R14 antibody.
Afterwards, a dose of 10 mg/kg of antibody NIMP-R14,
0.2 ml of clo-lip and 0.5 ml of HuRBC was injected i.p. at
3 days interval, until the end of the study. The follow-up
of the infection was performed by daily Giemsa stained
thin blood films drawn from the tail vein.
Haematological parameters and grafting of P. falciparum-
HuRBC
The study blood samples were collected from mice retro-
orbital sinus on heparin. Various haematological parame-
ters such as haematocrit, leukocyte number and pheno-
type (Ly-6C APC, Ly-6G APC (Miltenyi Biotec,
Germany), CD115 PE, CD43 FITC, CD62L FITC, CD11b
FITC, DX5 FITC, CD122 PE (BD Biosciences, UK) in
peripheral blood samples were monitored, as well as the
phenotype characterization of monocytes (CD11b+,
CD115+), inflammatory monocytes (CD43-, CD62L+, Ly-
6C+), PMN (CD11b+, ly6G+), and natural killer cells
(DX5+, CD122+). Total leukocyte number (leukocytes/μl
blood) was evaluated by lysing 20 μl of total blood with
BD FACS™ Lysing solution, and counting on Malassez
haematocytometer. Since successfully grafted mice have a
significant, but variable, percentage of HuRBC in their
peripheral blood, parasitaemia in mice was expressed as
the overall percentage of P. falciparum infected RBC
among total RBC, i.e. both human and mouse RBC
observed in thin blood smears. In addition, the peritoneal
blood parasitaemia was measured in the smears drawn
from the peritoneum. The percentage of HuRBC in the
peripheral blood of mice was determined by an immuno-
fluorescence technique using a FITC labeled anti-human
glycophorin A monoclonal antibody (DAKO, Denmark).
Assay of cytokines and chemokine
100-150 μl blood samples were collected from the retro-
orbital sinus with the help of Pasteur pipette, and sera
were stored at -80°C. Cytokines (IL-6, MCP-1, IFNγ,
TNFα, IL-12p70 and IL-10) were quantified using the
BD™ Cytometric Bead Array mouse inflammatory kit fol-
lowing the manufacturer's recommendations.
Statistical analysis
The paired test was used for statistical analysis. P values
of less than 0.05 were considered significant. In the
results section only differences reaching significance are
mentioned.
Results
Various patterns of peripheral blood parasitaemia are 
observed in NOD/SCID mice
Although stable long-lasting parasitaemia could be
obtained and employed for various applications [8,11] the
pattern of parasitaemia has never been homogeneous, i.e.
varied greatly from one animal to the other, and the vari-
ous attempts to modify the protocol failed to improve
results significantly. For instance, among a total of 84
mice studied recently under rigorous and well-controlled
conditions using the standard immunomodulation proto-
col described above, four different patterns of peripheral
blood parasitaemia could be described (summarized in
Figure 1). Following a single infection by P. falciparum,
17% of mice remained parasitologically negative, 34%
showed a transient parasitaemia lasting for ca. 12 days
post-infection, 12% showed a stable parasitaemia for
more than 20 days and 37% showed an almost total para-
Figure 1 Patterns of blood parasitaemia observed in NOD/SCID 
mice. In four independent experiments, a total of 84 NOD/SCID mice 
were infected with a single i.p. infection of P. falciparum 3D7 strain on 
day 0 and HuRBC (500 μl of pellet at 50% haematocrit), clo-lip (200 μl) 
and NIMP-R14 (10 mg/kg) antibody were injected i.p. every 3 days as 
previously described (black arrows). The preparatory phase prior to the 
injection of infected HuRBC is not shown. Parasitaemia was measured 
on tail blood smears by counting the number of infected RBC among 
10000 total human and mouse RBC. Parasitemia lower than 0,001 are 
not considered. The figure shows the average parasitaemia ± SD, and 
the percentages (and number of mice) corresponding to each pattern 
of parasitemia.Arnold et al. Malaria Journal 2010, 9:197
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site clearance from peripheral blood, however followed
by a re-emergence a few days later, without new parasite
inoculation, i.e. a second wave of parasitaemia lasting for
the life-span of the animal. The sequence of events of the
latter pattern considered the most informative, was
selected for further analysis.
Various modifications to the standard protocol were
assessed, and resulted only in differences in the propor-
tion of mice presenting the four patterns of parasitaemia
described above. These modifications include: 1) varia-
tions in the dose and schedule of administration of the
different components (i.e. infected and uninfected
HuRBC, clo-lip and NIMP-R14, including modifications
proposed by others [12]); 2) use of various agents to
reduce innate immunity, such as cyclophosphamide, cis-
platinium, irradiation, dexamethasone, TGF-β, splenec-
tomy, TMβ-1 antibody targeting NK cells 3) Addition of
metabolic precursors such as pABA, folinic acid to supply
nutritive factors for the parasite 4) Addition of antioxi-
dants such as vitamin E, N-acetyl cysteine (NAC), trolox,
8-aminoguanidine. These empirical approaches never
brought a significant or reproducible improvement of
parasite survival in NOD/SCID mice.
These results raise the question of which factor(s) are
critical to control in order to obtain a stable parasitaemia
and prompted the launch of a detailed analysis of the
remaining innate immune defences, mainly MP and
PMN.
The strong inflammation induced by P. falciparum is 
associated with parasite clearance
In mice showing a recrudescence (fourth pattern
described above, which was thought to be the most dis-
criminating, see Figure 1) the following parameters were
analysed in kinetic manner: 1) the numbers and pheno-
type of blood leukocyte subsets, 2) various cytokines
serum levels, 3) HuRBC grafting in the peripheral blood,
together with 4) parasitaemia.
Results, summarized in Figure 2A, show that, whereas
parasitaemia in peritoneal blood remains stable over
time, conversely, peripheral blood parasitaemia decreases
markedly. This decrease is related to a major clearance of
HuRBC in this compartment, despite repeated blood
injections, which is parasite-dependant since the num-
bers of circulating HuRBC in control, uninfected mice,
remain stable (see below).
The parasite was found to induce a very potent pro-
inflammatory effect characterized by a transient increase
in peripheral leukocytes numbers mostly monocytes
(MO) (1690 ± 1080 MO/μl on day 7 post-infection vs 290
± 125 on day 0, i.e. 5.8 fold increase; P < 0.006) and to a
lesser extent PMN (3000 ± 1500 PMN/μl on day 3 post-
infection vs 2100 ± 750 on day 0, i.e. 1.4 fold increase; not
significant) (Figure 2B). Moreover, during the first few
Figure 2 P. falciparum is highly pro-inflammatory. (A) Peripheral 
(plain circles) and peritoneal (open circles) parasitaemia (average of 31 
mice ± SEM) counted on blood smears and percentage of human gly-
cophorin A+ RBC grafted in mouse peripheral blood detected by FACS 
among total RBC (full circle, dotted line). Parasitemia lower than 0,001 
are not considered. (B) Total number of leukocyte per μl of blood (plain 
circle) at different times post-infection. The numbers of CD11b+ F4/80+ 
monocytes (black square, dotted line) and CD11b+ Ly-6G+ PMN (white 
triangle) were calculated from the percentages obtained by FACS anal-
ysis. The percentage of CD43- CD62L+ Ly-6C+ inflammatory monocytes 
was also assessed by FACS (open circle, dotted line). (C) Cytokines/
chemokine levels were estimated using the CBA mouse inflammatory 
cytokines kit by FACS. (D) Representative peritoneal blood smears 
showing the progressive phagocyte recruitment following P. falcipar-
um infection. Results represent the means ± SEM from 3 distinct exper-
iments (n = 14 mice).Arnold et al. Malaria Journal 2010, 9:197
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days following the infection, a transient increase (Figure
2 B )  i n  b l o o d  M O  h a v i n g  a n  i n f l a m m a t o r y  p h e n o t y p e
CD43- CD62L+ Ly-6C+ was observed (57.2 ± 12.7% of MO
on day -1 before infection vs 80 ± 11% on day 3 post-
infection; P < 0.03) (the Gr-1 antigen is not expressed on
NOD/SCID MO surface). In addition, the parasite
induces a major recruitment of leukocytes in the perito-
neal cavity as compared to controls receiving uninfected
HuRBC (Figure 2D).
The peak of blood MO was associated with a peak of
secretion of several inflammatory cytokines such as IL-
12p70 (342 ± 520 pg/ml on day 7 post-infection vs 33 ±
6.5 pg/ml on day -1 before infection), IFNγ (290 ± 215 pg/
ml on day 7 vs 5 ± 2.2 pg/ml on day -1) and TNFα (155 ±
53 pg/ml on day 7 vs  53 ± 26 pg/ml on day -1) or
chemokine such as MCP-1 (from 355 ± 290 pg/ml on day
-1 to 960 ± 480 pg/ml on day 7 post-infection) (P < 0.009).
Results attest of the strong inflammation induced by
the parasite; however the latter is transient, (Figure 2C)
and accordingly the number of leukocyte decreases to
reach values close to the steady state.
T h e  d e c r e a s e  i n  p a r a s i t e - i n d u c e d  i n f l a m m a t i o n  w a s
followed by a new increase in HuRBC numbers in periph-
eral blood, which understandably correlated with a recru-
descence of P. falciparum blood parasitaemia. This
second wave of parasitaemia itself induced an increase of
leukocyte counts, of IL-6 and MCP-1, however not of IL-
12p70, IFNγ and TNFα, and in addition, was not associ-
ated with a re-emergence of inflammatory MO. Hence,
the secondary parasitaemia was less pro-inflammatory
than the first. This also point to an important role for
inflammatory MO in the initial clearance of uninfected
and P. falciparum infected HuRBC.
Plasmodium yoelii is far less pro-inflammatory than P. 
falciparum
Innate immune responses triggered by P. falciparum were
compared with those elicited by the murine non-lethal
parasite P. yoelii XNL 1.1 strain. In contrast to P. falci-
parum, P. yoelii induced an exponential increase in para-
sitaemia in immunodeficient NOD/SCID mice reaching
more than 60% within two weeks (Figure 3A), accompa-
nied by a major drop in haematocrit (52 to 18% by week
2), and ultimately led to the death of the animals. An
increase in the numbers of circulating leukocytes
occurred, but was delayed, until parasitaemia was already
high (ca. 10%) (Figures 3A and 3B). The number of leuko-
cytes increased 3.5 fold from day 7 (2600 ± 800 leuko-
cytes/μl) to day 15 (9100 ± 2250) post-infection (P <
0.004). This was mainly due to a 4.2 fold increase in PMN
from day 11 (1060 ± 630) to 15 (5500 ± 1300) (P < 0.008).
There was a major, 7.1 fold, increase of NK cells from day
7 (95 ± 50 NK cells/μl) to day 15 (675 ± 180) (P < 0.001),
and a lower, 2.2 fold, increase in MO from day 4 (560 ±
230 MO/μl) to 7 (1200 ± 390) (P < 0.013).
Plasmodium yoelii infection did not induce the strong
inflammation characteristic of P. falciparum. Only MCP-
1 was detected to a significant level (145 pg/ml till the end
of the study) but its basal level was already elevated (80
Figure 3 P. yoelii is far less pro-inflammatory than P. falciparum. 
P. yoelii non lethal XNL 1.1 strain was injected i.p. in NOD/SCID mice 
and the same parameters as in P. falciparum infected mice were as-
sessed (see the legend of figure 2). (A) Peripheral blood parasitaemia; 
(B) Total number of leukocyte per μl of blood (plain circle) at different 
time post-infection. The numbers of CD11b+ F4/80+ monocytes (black 
square, line dot) and CD11b+ Ly-6G+ PMN (white triangle) were calcu-
lated from the percentages obtained by FACS analysis. The percentage 
of CD43- CD62L+ Ly-6C+ inflammatory monocytes was also assessed by 
FACS (open circle, dotted line); (C) Cytokines/chemokine levels deter-
mined using the CBA mouse inflammatory cytokines kit. Results repre-
sent the means ± SEM from 2 distinct experiments (n = 5 mice).Arnold et al. Malaria Journal 2010, 9:197
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pg/ml) (Figure 3C). The other cytokines assayed did not
show any significant increase as compared to basal level
(Figure 3C). Moreover, P. yoelii did not induce the strong
increase of CD43-  CD62L+  Ly-6C+  inflammatory MO
which was very significant with P. falciparum (Figure 2B),
but only several moderate variations (i.e. a small initial
increase from 30.6 ± 6.5% on day 0 to 41.7 ± 5.2% on day 2
post-infection (P < 0.0045) followed by a temporary
decrease, 15.2 ± 7.3% on day 7 post-infection (P < 0.0045)
then by a new increase to reach steady state value on day
15 post-infection) (Figure 3B). In the absence of adaptive
immune responses, all mice infected with P. yoelii died
between day 16 to day 20 post-inoculation (not shown).
HuRBC, and anti-inflammatory agents, induce low-grade 
inflammation
Considering the indications that inflammation was
related to the clearance of the parasite, it was decided to
examine whether HuRBC, clo-lip and NIMP-R14 anti-
body also induce inflammation. The effects of each com-
ponent, injected i.p. upon 1) the number and phenotype
of blood leukocytes, and 2) cytokines serum levels, were
examined. The inflammatory effect of HuRBC was not
unexpected, as it represents a heterologous graft. The i.p.
injection of HuRBC induced an increase in leukocyte
numbers (Figure 4A) (P < 0.003 between day 0 and day 3)
mainly PMN and to a lesser extent MO and NK cells (data
not shown). The inflammatory MO subset increased
transiently to peak at 76% of total MO 10 hours post
infection (P < 0.009), and then progressively decreased to
basal level (Figure 4B). HuRBC grafting also led to a tran-
sient secretion of IL-6 (732 ± 51 vs 47 ± 14.7 pg/ml; P <
0.003) and TNFα (216 ± 51 pg/ml vs 75 ± 79 pg/ml; P <
0.1) (Figures 4C and 4E), without substantial modifica-
tions of MCP-1, IL-10, IL-12p70 or IFNγ.
Unexpectedly, it was observed that clo-lip induce a fast
and strong inflammatory reaction. Indeed, as soon as
three hours post liposomes injection, the number of cir-
culating leukocyte increased by 6.8 fold (Figure 4A) (MO
3.14 fold, PMN 8.8 fold and NK 3.07 fold) (P < 0.01), and
thereafter, decreased but slowly (remaining four times
higher than basal level 48 hours post-injection). In addi-
tion, clo-lip induced an increase of the "inflammatory"
MO subset (CD43- CD62L+ Ly-6C+) that lasted for more
than three days (Figure 4B) (P < 0.001). Clo-lip injection
also led to a transient release of IL-6 (777 ± 445 vs 48 ± 30
pg/ml at 3 hours post-injection) (Figure 4C) (P < 0.03).
Finally, the anti-PMN monoclonal antibody NIMP-R14
had a modest effect on the number of leukocytes and on
the percentage of inflammatory MO, but was the stron-
gest inducer of IL-6 (1054 ± 292 vs 30 ± 7 pg/ml at 3
hours post-injection) and of MCP-1 (2425 ± 760 pg/ml at
3 hours post-injection) (Figure 4C and 4D), and also
induced the release of TNF(133 ± 19 vs 24 ± 3.7 pg/ml at
3 hours post-injection) (Figure 4E) (P < 0.04).
Figure 4 HuRBC, clo-lip and NIMP-R14 antibody are pro-inflam-
matory. HuRBC (full circle, plain line), clo-lip (open circle) and NIMP-
R14 antibody (full circle, dotted line) were injected once in the perito-
neum at hour 0, at doses identical to those used for the whole immu-
nomodulation protocol. Leukocyte number (A), CD43- CD62L+ Ly-6C+ 
inflammatory monocytes (B) and inflammatory cytokines/chemokine 
(C-E) were assessed in mouse peripheral blood by FACS. Results are 
the means ± SD. from groups of 4 mice.Arnold et al. Malaria Journal 2010, 9:197
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Altogether these results indicate that the immunomod-
ulators clo-lip and NIMP-R14 antibody, which have pre-
viously been shown to be indispensable to the grafting of
P. falciparum, actually reduce innate responses, though at
the expense of a transient but substantial inflammation.
The repeated injection of HuRBC, clo-lip and anti-PMN 
reduces inflammation and improves HuRBC grafting
The intriguing results above led to analyse the events
spanning the 13 days of the immunomodulation protocol
preceding the injection of the parasite. This protocol con-
sists in four co-injections of HuRBC, together with clo-lip
and NIMP-R14 antibody, to prepare the host to the infec-
tion as suggested by others [12]. A progressive decrease
of inflammation during the immunomodulation protocol
was observed. At the end, the levels of cytokines were
lower (Figure 5B) than those induced by a single injec-
tion, for IL-6 (146 ± 43 vs 527 ± 175 pg/ml), MCP-1 (322
± 31 vs 580 ± 58 pg/ml), and TNF(40 ± 12 vs 72 ± 12 pg/
ml) (P < 0.03). The number of leukocytes and the per-
centage of CD43-  CD62L+  Ly-6C+  MO also decreased
over time (Figures 5C and 5D) (P < 0.05). These changes
resulted in an improved grafting of HuRBC as compared
to a single injection (35.6 ± 14.3% vs ca. 10%) (Figure 5A).
MO/MP are critical in controlling P. falciparum and HuRBC 
grafting in NOD/SCID mice
An attempt was made to identify the cell subset most crit-
ical in controlling P. falciparum in NOD/SCID mice. NK
cells are less numerous and functionally deficient in
NOD/SCID as compared to BXN mice. In addition, their
depletion by the TMβ-1 antibody did not result in any
improvement. Both observations do not point to a major
role of these cells (data not shown).
The rise in leukocyte numbers induced by P. falciparum
is predominantly due to an important increase in PMN
numbers, leading to legitimately suspect their involve-
ment. To explore the role of PMN, three different mono-
clonal antibodies were employed, that differ in their
efficiency to deplete PMN, namely 1A8, RB6-8C5 and
NIMP-R14 antibodies. 1A8 antibody led to a major
depletion of PMN for a period of ten days after infection,
whereas the other two had only a moderate effect.
Despite these differences, the resulting parasitaemia were
essentially similar, which does not designate PMN as a
main effector against infected HuRBC (Additional file 1).
The above results led to address the role of MO and of
the large MP derived from them. Firstly, MP is the main
subset of phagocytes recruited into the peritoneum all
over the course of infection (Figure 6A) (P < 0.05). Sec-
ondly, they were found to be the most active, and in par-
ticular more active than PMN at ingesting both infected
and non-infected HuRBC in the peritoneum (Figure 6B
and 6C upper panel) but also in the spleen (Figure 6C
Figure 5 Graft of HuRBC and markers of inflammation during the 
immunomodulation protocol. (A) The percentage of HuRBC grafted 
in mouse peripheral blood was assessed by FACS by using an anti-hu-
man glycophorin A antibody, after several co-injections of HuRBC, clo-
lip and NIMP-R14 antibody into the peritoneum (black arrows). (B) Cy-
tokines/chemokines were assessed in mouse sera by FACS using the 
CBA mouse inflammatory cytokines kit. (C) Leukocyte number. (D) 
CD43- CD62L+ Ly-6C+ inflammatory monocytes were assessed by 
FACS. Results are means ± SEM of 2 experiments (n = 15 mice).Arnold et al. Malaria Journal 2010, 9:197
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lower left panel) and in the liver (Fig 6C lower right
panel). Moreover, clo-lip target only circulating MO and
MP, and Figure 6D clearly shows that clo-lip is necessary
for the grafting of HuRBC: the percentage of circulating
HuRBC was 54 ± 2% after three clo-lip injections vs 0.95
± 0.93% without, or 4.1 ± 2% with the anti-PMN NIMP-
R14 antibody. Altogether, these results point to the MO/
MP lineage as the most efficient component in control-
ling the graft of P. falciparum infected HuRBC.
Discussion
Results confirm that innate defences are potent against
xenografts and pathogens in mice lacking T, B and NK
cell functions, and provide an insight of their effect
against P. falciparum in immunodeficient mice. Several
years ago, our group has taken advantage of immuno-
compromized mice, i.e. mice genetically defective in their
adaptive immunity, to generate a P. falciparum mouse
model, which could be successfully used for several types
of applications such as assessment of antibodies directed
to new vaccine candidates [6,7,11] or of anti-malarial
drugs [8] with any P. falciparum strain or isolate [12]. The
repeated injection into the peritoneum of HuRBC, clo-lip
and NIMP-R14 antibody allowed P. falciparum growth in
mouse peripheral blood, but at the expense of a high fail-
ure rate, since only a subset harboured a stable parasitae-
mia (i.e. 12% among several hundred NOD/SCID mice
tested have a stable parasitaemia and 37% have a recru-
descent parasitaemia). Therefore, it was decided to focus
further work on the analysis of murine innate immune
defences induced by this very pro-inflammatory parasite
in order to gather an understanding, i.e. to attempt to
identify the critical defence component(s) limiting suc-
cessful grafting.
The present study shows that 1) P. falciparum induces a
major inflammation characterized by an increase in
peripheral leukocytes and by the release of inflammatory
cytokines in the serum; 2) parasitaemia in the perito-
neum remains stable whereas the decrease observed in
the peripheral blood is related to HuRBC clearance in this
compartment, triggered by the parasite; 3) P. yoelii,
induces a very moderate inflammation as compared to P.
falciparum, suggesting that a parasite adapted to its host
does not trigger the same inflammatory response (which
may be related to host factors, for example a lower recog-
nition by host receptors, and/or to parasite factors, for
example a lower production of pro-inflammatory mole-
cules presented by this parasite); 4) clo-lip, NIMP-R14
and HuRBC also induce an inflammation, but far less
important than that triggered by the parasite itself, and
the former is anyhow essential to parasite grafting; 5)
none of the additional immunosuppressive, anti-inflam-
matory, anti-oxidant and nutritive factors assessed in
empirical manner was able to significantly, or reproduc-
Figure 6 Evaluation of the role of PMN, and of monocytes/mac-
rophages, in the graft of infected and non-infected HuRBC. A peri-
toneal smear was drawn at different times post-infection in order to 
assess the phenotype of peritoneal phagocytes. (A) MP (black bar) and 
PMN (white bar) were identified by microscopy in order to determine 
the percentage of each subset among the total number of phagocytes 
counted on the smear (at least 500). (B) Percentages of MP (black bar) 
and PMN (white bar) having ingested at least one particle of malaria 
pigment. Results are the mean ± SD from 4 infected NOD/SCID mice. 
(C) Representative Giemsa staining of different organs smears per-
formed 45 days post-infection from 3 different NOD/SCID mice (upper 
panel left and right: peritoneum; lower left panel: spleen, lower right 
panel: liver). Arrows indicate haemozoin loaded MP. (D) Effect of clo-lip 
and NIMP-R14 antibody on HuRBC grafting in NOD/SCID peripheral 
blood. HuRBC are injected alone (Black square) or in combination with 
clo-lip (plain circle) or with NIMP-R14 antibody (open circle). Black ar-
rows represent the days of injection. Results are means ± SEM of 2 ex-
periments (n = 6 mice per group).Arnold et al. Malaria Journal 2010, 9:197
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ibly, improve P. falciparum survival; and 6) MP seem to
bear the most critical function in controlling P. falci-
parum in these mice.
The innate immune defences that remain in immuno-
compromized mice have seldom been analysed. Surpris-
ingly, only one study has so far focused on this issue. It
reported the occurrence of a major inflammation in rela-
tion to human leukocytes grafting in SCID mouse perito-
neum [13]. It consists in a massive and early (24 h)
recruitment of neutrophils and in the secretion of a wide
spectrum of murine cytokines, such as IL-6, TNF, IFNγ,
IL-1β, IL-10, IL-12p40 in the peritoneal cavity. The role
of granulocytes is supported by improved engraftment of
human leukocytes following administration of the anti-
granulocyte antibody RB6-8C5 [14]. Since this report,
innate immune responses in immunocompromized mice
have remained surprisingly little explored, despite the
general agreement that they are very efficient in defence
against xenografts [15,16]. Even NOD/SCID/IL-2rγ-/-
mice, which present substantial additional defects in
innate immunity (they lack functional T, B and NK cells,
have reduced functions of MP and dendritic cells, and
several cytokines pathways are totally impaired) still
require the use of pharmacological agents or irradiation/
splenectomy to allow for the grafting of cells of human
origin [15,17].
The present study model includes a "double xenograft",
of HuRBC and of P. falciparum. A first limitation of this
model is the lack of understanding of the transperitoneal
passage of both uninfected and infected HuRBC in mouse
peripheral blood, and its lack of reproducibility (17% of
mice were negative). The i.p. route of administration of
HuRBC was chosen as it was previously found effective
using bovine RBC [2], as it constitutes a reservoir
whereas HuRBC injected i.v. are quickly eliminated [18].
However, the mechanism of passage being unknown,
though there are indications for lymphatic drainage
[19,20], the reasons for occasional blockade are even less
clear. There might be a pure mechanical component as
the simple increase in HuRBC volume (2 ml at 50% hae-
matocrit daily) led us and others [21] to improve HuRBC
chimerism in peripheral blood. Secondly, the increase of
clearance of HuRBC (both infected and non-infected) 7
to 10 days after injection of the parasite, is likely inflam-
mation dependent as it was found to be associated with a
concomitant peak of inflammatory cytokines and
chemokine (IL-12p70, IFNγ, TNFα and MCP-1) in mouse
serum. TNFα is known to increase erythrophagocytosis
and to induce anaemia during malaria both in mouse and
in human [22]. Splenectomy improves HuRBC grafting,
suggesting that splenic MP play a role in this clearance
[21,23]. Thirdly, in those rare cases (5%) when the perito-
neum cavity was invaded by millions of MP this resulted
in HuRBC phagocytosis, and clearance of the graft in this
compartment.
Together these data suggest a prominent role of MP in
the rejection of both uninfected and infected HuRBC by
two main mechanisms: the release of inflammatory medi-
ators reflecting the activation of MO and the resulting
increased erythrophagocytosis. The role of MP in xeno-
graft rejection is well documented [24]. For instance they
account for the majority of infiltrating leukocytes during
the rejection of pig-to-primate xenografts [25,26] and
selective MP depletion in immunocompetent rodents
resulted in significant delays in cellular infiltration and
xenograft rejection [27,28]. Finally, clo-lip which depletes
MO/MP was clearly essential to both HuRBC and P. falci-
parum survival, stressing also in this model the impor-
tance of MP.
The mechanism of HuRBC phagocytosis by murine MP
is yet to be elucidated. It can not be due to complement or
by Fc receptors-mediated opsonization, as NOD/SCID
mice have neither complement activity [29] nor antibod-
ies [29,30]. C-type lectins integrated in MP membrane
have been reported to mediate erythrophagocytosis by
directly binding to sugar ligands on the surface of senes-
cent or altered RBC [31,32]. Moreover, the signal regula-
tory protein a (SIRPα) is a critical immune inhibitory
receptor on MP that reacts with CD47 to prevent autolo-
gous phagocytosis. Since CD47 is species specific,
healthy HuRBC may be phagocytozed by murine MP due
to their inability to induce murine MP SIRPα tyrosine
phosphorylation [33,34]. Conversely, phagocytosis of P.
falciparum infected HuRBC by MP is well documented,
and the scavenger receptor CD36, which recognizes
PfEMP-1 on the surface of infected RBC, is widely impli-
cated in this process. Indeed, P. falciparum phagocytosis
decreases by 80% using blocking antibodies or CD36-/-
murine MP [35,36]. MP also possess a large array of
pathogen-recognition receptors such as toll-like recep-
tors (TLRs) that recognize P. falciparum GPI anchors,
that are considered as key malaria pathogenicity factors
[37,38]. TLR-2 and to a lesser extent TLR-4 directly rec-
ognize infected RBC [39] whereas TLR-9 recognize only
the haemozoin pigment [40-42], but all trigger inflamma-
tion through the MyD88/NFκB pathway. Uric acid
(derived from hypoxanthine accumulated by the parasite)
has been recently reported to be another major inflam-
matory mediator involved in P. falciparum infection [43].
The effect of haemozoin pigment on MO/MP is debated
as it was reported to impair their function such as block-
ing of phagocytosis [44-46], but also to be a potent proin-
flammatory agent. Indeed it can trigger the release of
NO, TNF, IL-6, IL-1β, MIP-1α, MIP-1β, MIP-2, MCP-1
and of many other mediators after in vivo administration
[47-49]. Successive effects, i.e. pro-inflammation fol-Arnold et al. Malaria Journal 2010, 9:197
http://www.malariajournal.com/content/9/1/197
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lowed by a relative anergy, may explain this apparent con-
tradiction. Whatever the complexity of the inflammatory
response induced by the parasite, it probably explains the
present observation, also made by another group, that the
injection of infected HuRBC induces a decrease of the
number of circulating HuRBC, either infected or not. The
results of the present study suggest that, whereas unin-
fected HuRBC induce a moderate inflammation, the par-
asite is a far more potent pro-inflammatory component
leading to a significant phagocytosis of HuRBC (both
infected and uninfected).
The remarkable efficiency of the innate immune system
to control plasmodium infection is in keeping with obser-
vations in humans: indeed, the parasitaemia recorded in a
primary malaria attack, in non-immune travellers, is usu-
ally quite modest, 0.1% on average (PLD, unpublished
observations in 700 infected European travellers),
whereas the theoretical 16×/48 h multiplication rate
would lead to heavy parasitaemia in the absence of strong
innate defences. Results in NOD/SCID show similarities
and differences with P. falciparum activation of innate
defences in humans. Recent studies performed in P. falci-
parum infected and exposed individuals have shown a
strong pro-inflammatory effect with an overall increase
in intermediate and inflammatory MO expressing
CD16+, mIFNγ and 2- to 10-fold increase in serum medi-
ators, such as IL-6, IL-10, IFNγ, TNF and MCP-1 [9].
However, two opposite phenotypes could be identified in
humans, based on chemokine receptors expression,
which corresponded to differences in activity in the anti-
body-dependent, MO-mediated ADCI mechanism of
defence and with 10 fold differences in the resulting para-
sitaemia in humans [9]. These two opposite phenotypes
can correspond either to true differences between two
groups of individuals or, alternatively, to successive states
of MO activation by the parasite at different time-points.
One of the patterns observed in NOD/SCID mice, where
parasitaemia and inflammation were followed by a
decrease of both, brings support to the latter view and is
reminiscent of the two states described in mouse MO
exposed to haemozoin. Finally, the observation that the
rodent parasite P. yoelii induces much less inflammation
than the human parasite in mice challenges the general
assumption that the evolution-driven adaptation of Plas-
modium to their respective hosts depends mainly on the
adaptive immune system, and indicates that the role of
non-adaptive immunity should be taken in consideration.
The fine molecular tuning of parasite molecules required
for the adaptation through the co-evolution of the para-
site with their usual host has most likely taken place for
molecules interacting with the adaptive immune system
("antigens") and for molecules interacting with the innate
defences. The numerous differences between P. yoelii and
P. falciparum observed in our study bring support to this
hypothesis.
More generally, the results of the present study stress
that a deficiency in adaptive immunity is far from being
enough to ensure the success of xenografts. It is also
essential to control innate defences (which can not be
knocked out safely). In this respect, P. falciparum-SCID
mice constitute a convenient model as the effect of innate
defences is readily visible within hours, in contrast with
other types of grafts (e.g. lymphocytes). However, innate
immunity proved as efficient as it is difficult to control.
Three strategies have been used for this purpose. Firstly,
splenectomy improved P. falciparum survival in NOD/
SCID mice [18]. Secondly, the suicide-based approach
developed by Van Rooijen with clo-lip [5], despite its par-
adoxical inflammatory effect, was nonetheless efficient at
depleting MP. Clo-lip proved essential at successful graft-
ing of P. falciparum erythrocytic stages as well as human
hepatocytes and P. falciparum liver stages in uPA-SCID
[50]. Yet, a single clo-lip i.p. injection led to an increase of
leukocytes, an increase of the CD43- CD62L+ Ly-6C+ MO
subset and an increase of IL-6 and MCP-1. These results
suggest that conclusions from studies using clo-lip in
mice should be interpreted with care. A third, and likely
more satisfactory, strategy relies on the generation of
mice with improved genetic deficiency of innate immu-
nity. In this respect, the NOD/SCID/IL2rγ-/- (NOG) mice
open new perspectives [1,51], but simultaneously stresses
the need for further efforts in the same direction. Indeed,
NOG mice are not as good recipient of human skin and
artery as SCID/bg mice [15], and, NOG reconstituted
with CD34+ haematopoietic stem cells did not sustain the
development of human B cells, and most T cells could
neither proliferate nor produce IL-2 in response to anti-
genic stimulation [17]. These results indicate that further
improvements in genetic deficiencies are necessary. This
in turn implies to better identify the molecular mecha-
nisms critical in graft rejection.
Conclusions
Taken together data presented in this study show that
immunocompromized mice such as NOD/SCID mice in
which the number of MP and PMN are controlled to a
certain extent by repeated injection of clo-lip and NIMP-
R14 antibody respectively, are still able to mount substan-
tial innate defences against xenografts, notably HuRBC
and  P. falciparum. Moreover, the immunomodulatory
treatment itself induced inflammatory responses. These
results indicate that the use of SCID mice to study human
disease need to be carefully interpreted and that further
improvements are required to obtain a mouse model fully
receptive to grafts of foreign origin.Arnold et al. Malaria Journal 2010, 9:197
http://www.malariajournal.com/content/9/1/197
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